Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
TORONTO, March 07, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that management will participate in the Oppenheimer Annual Healthcare Conference as part of the biotechnology virtual corporate presentation on Tuesday, March 14, 2023 at 4:00 PM Eastern Time / 1:00 PM Pacific Time.
Related news for (REUN)
- Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
- Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
- KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
- KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th